bb2121

Shares of bluebird bio Inc (NASDAQ: BLUE) — a clinical-stage biopharmaceutical company focused on bringing to market advanced products based on the potential of gene therapy — have been highly volatile, but the company has a "clear path" toward commercialization,...

Bluebird bio Inc (NASDAQ: BLUE), a clinical-stage biotechnology company that focuses on therapies for the treatment of severe diseases and cancer, released "highly encouraging" clinical data in late 2017, according to Janney. But that doesn't mean investors should be aggressive buyers...

Shares of bluebird bio Inc (NASDAQ: BLUE) gained more than 200 percent in value last year and investors can expect 2018 to be another "blue-ribbon year" for the stock, according to William Blair. The Analyst Willaim Blair's Raju Prasad initiated coverage of bluebird bio's...

Bluebird bio Inc (NASDAQ: BLUE)'s multiple myeloma therapy coud have a "disruptive impact" on treatment of the disease, according to Goldman Sachs. The Analyst Goldman Sachs' Salveen Richter maintains a Buy rating on bluebird's stock and raised the price target from $186 to...

Bluebird bio Inc (NASDAQ: BLUE)'s encouraging data release over the weekend has many experts and Wall Street analysts excited about the company's prospects in treating sickle cell disease. The Analyst Jefferies' Biren Amin upgraded bluebird's stock rating from Hold to Buy with a...

bluebird bio Inc (NASDAQ: BLUE) reported compelling data over the weekend at the American Society of Hematology that some experts described as "unheard of." The Analyst Cantor Fitzgerald's Elemer Piros reiterated an Underweight on bluebird's stock with a price target...

Shares of bluebird bio Inc (NASDAQ: BLUE) have gained 75 percent since the start of 2017, which prompted analysts at BTIG to downgrade the biotech company at the forefront of fighting against cancer. BTIG's Dane Leone downgrades Bluebird's stock rating from Buy to Neutral as many of the bullish...

Citing the release of new bb2121 therapy data among other growth factors, BMO analyst Matthew Luchini has upgraded bluebird bio Inc (NASDAQ: BLUE) to Outperform and raised his price target to $108. “We believe latest data shows bb2121's continued compelling efficacy, including 100 percent...

Wedbush analyst David Nierengarten maintains his Outperform rating and $95 target price on bluebird bio Inc (NASDAQ: BLUE), which announced positive results from its early-stage cancer study. Cambridge, Massachusetts-based bluebird bio said early data from its ongoing Phase 1 study of bb2121 showed...

In a classic example of how trial results can impact stock prices, shares of Heat Biologics Inc (NASDAQ: HTBX) plunged 58 percent in the Thursday’s pre-market hours following a negative outcome of its bladder cancer study, while bluebird bio Inc (NASDAQ: BLUE)’s impressive early cancer...